| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 30.6 | 27.8 |
| Gross profit | 18.8 | 15.6 |
| Profit before tax | -0.3 | -2.2 |
| Net income | -0.3 | -2.3 |
| EPS (diluted, $ a share) | $-0.02 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.0% |
|---|---|
| Gross margin | 61.6% |
| Operating margin | -2.3% |
10-Q filed with the SEC, NASDAQ: ANIK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Anika Therapeutics, Inc.: key numbers
- Share price
- $12.85Close, Nov 17
- Market cap
- $172M
- Shares outstanding
- 13.4MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Anika Therapeutics, Inc.
All →Anika Therapeutics Financial Results
Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, a 10% increase year-over-year driven by 17% growth in its Commercial Channel. The company raised the lower end of its full-year revenue guidance and increased its Adjusted EBITDA outlook following strong performance in its Integrity and international viscosupplement lines.
- Term
- Q3 2026
“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption.”
Steve Griffin, President and Chief Executive Officer